In the AML study found that nearly 10% of patients with TET2 gene mutation, and the mutation is heterozygous mutations, wild-type allele has not changed, indicating that TET2 may play a role in inhibiting the occurrence of tumors [29]. This evidence concerns the gene TET2 and acute myeloid leukemia.